{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-26-000010","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2026-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.106426+00:00","generated_at":"2026-05-16T04:07:23.088821+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunovant reports Q3 net loss of $110.6M; cash $994.5M; D2T RA trial fully enrolled","bullets":["Net loss $110.6M ($0.61/sh) for Q3 FY26; non-GAAP net loss $97.5M.","Cash and equivalents $994.5M post-$550M financing; runway to GD commercial launch.","D2T RA potentially registrational trial fully enrolled; topline data H2 2026.","Batoclimab Phase 3 TED data expected H1 2026; IMVT-1402 GD and MG topline in 2027.","R&D expenses $98.9M, up from $94.5M YoY; driven by IMVT-1402 clinical activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-26-000010","json":"https://secwatch.observer/filing/0001764013-26-000010.json","markdown":"https://secwatch.observer/filing/0001764013-26-000010.md","text":"https://secwatch.observer/filing/0001764013-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/0001764013-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/imvt-20260206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:07:23.088821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}